Abstract

The present invention belongs to the medical field. Specifically, it relates to a method based on the detection of biomarkers to identify whether a subject treated with bone-modifying agents (BMAs) may develop medication-related osteonecrosis of the jaws (MRONJ), to assess whether it is advisable to carry out an invasive dental procedure in subjects treated with BMAs, and/or to select subjects treated with BMAs based on their risk of developing MRONJ.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

z2y1-x23m/n2-m3t3-t44 (C) as defined herein from which the material is obtained, and to the use of the material as electrocatalyst in different applications.

IPC Classes  ?

• C01G 45/02 - Oxides
• C01B 32/178 - OpeningFilling
• C01G 45/12 - Complex oxides containing manganese and at least one other metal element
• C01G 49/08 - Ferroso-ferric oxide [Fe3O4]
• C01G 51/04 - Oxides
• C01G 51/00 - Compounds of cobalt
• C01G 53/00 - Compounds of nickel
• C25B 1/21 - Manganese oxides
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy
• C25B 1/01 - Products
• C25B 11/054 - Electrodes comprising electrocatalysts supported on a carrier
• C25B 11/065 - Carbon
• C25B 11/077 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the compound being a non-noble metal oxide

Abstract

The present invention relates to microparticles for pulmonary release that comprise a purified pollen capsule, which comprises an intine layer and an exine layer, and at least one nanosystem encapsulated in said capsule. Said nanosystem comprises a pharmaceutically active compound, wherein the exine layer is coated with a pharmaceutically acceptable excipient. The present invention further relates to a method for obtaining said microparticles and medical uses thereof, in particular for the treatment of tuberculosis.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61P 31/06 - Antibacterial agents for tuberculosis

Abstract

in vitroin vitroin vitro method for recommending whether to treat patients suffering from cancer with PD-1 and/or PDL1 inhibitors, or for classifying patients suffering from cancer into responders or non-responders to a treatment with PD-1 and/or PD-L1 inhibitors.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Obestatin for use as antineoplastic agent in the treatment of pancreatic cancer. The present invention refers to the use obestatin as antineoplastic agent in the treatment of pancreatic cancer.

IPC Classes  ?

• A61P 5/48 - Drugs for disorders of the endocrine system of the pancreatic hormones
• A61K 38/25 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• C07K 14/60 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

OrthoreovirusOrthoreovirus muNS protein capable of forming microspheres and/or nanospheres, modified to permit the addition of polypeptides at the C-terminal.

IPC Classes  ?

• C07K 14/14 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
• A61P 31/14 - Antivirals for RNA viruses
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

The present invention refers to an in vitro method for the diagnosis, monitoring or prognosis of IGT/diabetes or prediabetes; or for screening or selecting patient candidates to be subjected to OGTT, which comprises assessing the amount of a protein, selected from the group consisting of: Retinol-Binding Protein 4 (Rbp), Alpha-l-acid glycoprotein (Agp), fibronectin (FN), and/or Complement factor H (CFH) which is bound to glycosaminoglycans (GAGs).

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Peptides for use as senotherapeutic agents. The present invention refers to senotherapeutic agents comprising different peptides for use in the prevention or treatment of aging-associated diseases caused by the persistence and accumulation of senescent cells.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

It is disclosed a family of ligands of GPVI of formula (I), or a pharmaceutically acceptable salt or solvate thereof: formula (I) as well as compositions comprising the same, for use as antiplatelet agents, in the prevention and/or treatment of thrombosis, as well as pathologies associated to thrombus formation such as: ischemic stroke, atherosclerosis, coronary artery disease or myocardial infarction, and, as well, as pharmacological tool for in-vitro inhibition studies interfering with platelet activation mediated by GPVI.

IPC Classes  ?

• A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Fragments of the N-Terminal domain of GSDMB for the treatment of cancer. The present invention generally refers to an isolated polypeptide comprising a fragment of the N-Terminal domain of GSDMB, wherein said fragment is characterized by comprising amino acid sequence 1-233 of the N-Terminal domain of GSDM-B or a functional equivalent thereof or a polynucleotide sequence coding for the said polypeptide, for use in the treatment of cancer.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 31/728 - Hyaluronic acid
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 49/00 - Preparations for testing in vivo
• A61P 35/00 - Antineoplastic agents
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Abstract

The invention relates to acrylic hydrogels comprising the myopia-suppressing agent atropine, and to methods for preparing the same. The hydrogels are capable of loading high quantities of atropine and releasing it in a sustained manner over an extended period of time suitable for overnight use.

IPC Classes  ?

• A61K 9/06 - OintmentsBases therefor
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61P 27/10 - Ophthalmic agents for accommodation disorders, e.g. myopia

Abstract

The invention relates to acrylic hydrogels comprising highly anisotropic gold nanoparticles, and to methods for preparing the same. The hydrogels of the invention are characterised by a light transmittance minimum at the 532-652 nm range of the electromagnetic spectrum and photothermal responsiveness to 808 nm wavelength irradiation.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 27/02 - Ophthalmic agents
• A61P 27/04 - Artificial tearsIrrigation solutions

Abstract

The present invention is focused on an in vitro method for the diagnosis or prognosis of Neurogenic Heterotopic Ossification (NHO) comprising assessing the expression level of Transforming Growth Factor Beta Induced (TGFBi) in a biological sample obtained from the subject that comprises astrocyte and/or nerve secretome. Moreover, the present invention also refers to a therapeutic strategy for treating NHO based on TGFBi inhibitors.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
• A61K 31/425 - Thiazoles
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Goods & Services

(1) Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biology, other than for medical or veterinary use; Nucleic acids; Nucleic recombinant acids; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processes [other than for medical use]; Biological tissue cultures, other than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing [other than for medical or veterinary purposes]; Biological preparations, other than for medical or veterinary purposes; Aldehydes; Active chemical ingredients; Salts [chemical preparations] (2) Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes; Medicines for human purposes; Biological preparations for medical purposes; Pharmaceutical preparations; Nutraceutical preparations for therapeutic or medical purposes; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Chemico-pharmaceutical preparations; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposes (1) Scientific and technological services, as well as related research and design services; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and/ or biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services (2) Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells; providing news and Providing information in the following fields: Pharmacy services; Provision of information relating to medicine; Human healthcare services

Goods & Services

Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biology, other than for medical or veterinary use; Nucleic acids; Nucleic recombinant acids; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processes (other than for medical use); Biological tissue cultures, other than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing (other than for medical or veterinary purposes); Biological preparations, other than for medical or veterinary purposes; Aldehydes; Active chemical ingredients; Salts (chemical preparations). Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes; Medicines for human purposes; Biological preparations for medical purposes; Pharmaceutical preparations; Nutraceutical preparations for therapeutic or medical purposes; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Chemico-pharmaceutical preparations; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposes. Scientific and technological services, as well as related research and design services; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and/or biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services. Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells; providing news and Providing information in the following fields: Pharmacy services; Provision of information relating to medicine; Human healthcare services.

Abstract

The invention relates to a method for the diagnosis of ulcerative colitis in a subject by detecting a nucleic acid target region and to oligonucleotides, oligonucleotide probes and kits to be used in this method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

2y/zxyx3yxx is an Atomic Quantum Cluster (AQC) consisting of x number of zero valent metal atoms; wherein G is Si or Ti; and y is an integer selected from 1, 2, 3, 4, 5 and 6; and wherein the compound of formula (I) has no net charge. In addition, the present invention is directed to a composition comprising the compound of formula (I), a process for producing the compound of formula (I); the uses of the compound of formula (I) and the compound of formula (I) for use as a medicament, its second medical uses, a pharmaceutical composition, kit-of-parts and an apoptotic agent comprising said compound of formula (I).

IPC Classes  ?

• C01B 33/20 - Silicates
• C01G 23/00 - Compounds of titanium
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

The invention lies in the field of delivery of nucleic acids into a cell. In particular, disclosed herein is a nucleic acid that is polyplexed with a polymeric scaffold, which is provided in combination with an endosomal escape-enhancing saponin that is covalently bound either to the polymeric scaffold or to a cell targeting ligand by a linker configured to release the saponin from the scaffold under conditions present in an endosome. The disclosed herein compositions and methods may be exploited in the treatment of various diseases and/or conditions by systemic delivery.

IPC Classes  ?

• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 35/00 - Antineoplastic agents

Abstract

The device comprises: a measuring chamber (1), in the form of a hollow cylinder made of a conducting material, through which an air current to be monitored circulates via natural or forced diffusion; a sensor element (2) with three or more planar semiconductor diodes (3) coplanar with the axial axis of the measuring chamber (1), said diodes being arranged along a section of the axial axis in a polygonal shape; a first polarisation source (41) which polarises the measuring chamber (1); a second polarisation source (42) which polarises the anode relative to the cathode; a signal amplifier (5); a discriminator (6); and a processor (7), on which a method with an instantaneous and/or continuous operating mode is performed, providing radon concentration values over measuring periods varying between 5 and 10 mins.

IPC Classes  ?

• G01T 1/24 - Measuring radiation intensity with semiconductor detectors

Goods & Services

Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biology, other than for medical or veterinary use; Nucleic acids; Nucleic recombinant acids; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processes [other than for medical use]; Biological tissue cultures, other than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing [other than for medical or veterinary purposes]; Biological preparations, other than for medical or veterinary purposes; Aldehydes; Active chemical ingredients; Salts [chemical preparations]. Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes; Medicines for human purposes; Biological preparations for medical purposes; Pharmaceutical preparations; Nutraceutical preparations for therapeutic or medical purposes; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Chemico-pharmaceutical preparations; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposes. Scientific and technological services, as well as related research and design services; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and/or biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services. Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells; providing news and Providing information in the following fields: Pharmacy services; Provision of information relating to medicine; Human healthcare services.

Goods & Services

Chemicals used in industry and science; Biological preparations for use in industry and science; Chemical reagents for molecular biology, other than for medical or veterinary use; Nucleic acids; Nucleic recombinant acids; Nucleic acids for scientific purposes; Nucleic acid for use in nucleic acid amplification processes [other than for medical use]; Biological tissue cultures, other than for medical or veterinary purposes; Reagents for use in scientific apparatus for chemical or biological analysis; Biological preparation for use in cell cultures other than for medical or veterinary use; Biological indicators for monitoring sterilization processes other than for medical or veterinary purposes; Reagents for use in biological processing [other than for medical or veterinary purposes]; Biological preparations, other than for medical or veterinary purposes; Aldehydes; Active chemical ingredients; Salts [chemical preparations]. Pharmaceuticals, medical and veterinary preparations; Sanitary preparations for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Biological reagents for medical use; Biological reagents for veterinary use; Biological adjuvants for medical purposes; Biological preparations for the treatment of cancer; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Medicines for human purposes; Medicines for human purposes; Biological preparations for medical purposes; Pharmaceutical preparations; Nutraceutical preparations for therapeutic or medical purposes; Chemical preparations for pharmaceutical purposes; Chemical preparations for medical purposes; Chemico-pharmaceutical preparations; Chemical reagents for medical or veterinary purposes; Chemical preparations for veterinary purposes. Scientific and technological services, as well as related research and design services; Research relating to molecular sciences; Analysis in the field of molecular biology; Research in the field of gene editing technology; Biological analysis; Biological development services; Biological laboratory services; Biological research and analysis; Services of a chemical and/or biological laboratory; Genetic mapping for scientific purposes; Scientific research in the field of genetics; Biological research; Scientific research; Culturing of cells for scientific research purposes; Medical research; Chemical research; Scientific laboratory services; Chemistry services. Medical services; Genetic testing for medical purposes; Medical treatment using cultured cells; providing news and Providing information in the following fields: Pharmacy services; Provision of information relating to medicine; Human healthcare services.

Abstract

The present invention refers to a process comprising 3-10 metal atoms atomic quantum clusters (AQCs) supported on metal oxides as catalysts for oxygen release; which can be applied to the oxidation of fuels. Additionally, the present invention refers to the use of said 3-10 metal atoms AQCs supported on metal oxides as oxygen carriers in chemical looping reactions, and to catalysts and chemical compositions comprising said 3-10 metal atoms AQCs supported on metal oxides.

IPC Classes  ?

• C01B 3/04 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of inorganic compounds, e.g. ammonia
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• B01J 35/00 - Catalysts, in general, characterised by their form or physical properties
• C01B 3/06 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of inorganic compounds containing electro-positively bound hydrogen, e.g. water, acids, bases, ammonia, with inorganic reducing agents
• B01J 21/00 - Catalysts comprising the elements, oxides or hydroxides of magnesium, boron, aluminium, carbon, silicon, titanium, zirconium or hafnium
• B22F 1/05 - Metallic powder characterised by the size or surface area of the particles
• C01B 3/40 - Production of hydrogen or of gaseous mixtures containing hydrogen by reaction of gaseous or liquid organic compounds with gasifying agents, e.g. water, carbon dioxide, air by reaction of hydrocarbons with gasifying agents using catalysts characterised by the catalyst

Abstract

The present invention relates to recombinant spriviviruses, in particular a recombinant spring viraemia of carp virus, uses thereof and methods for producing the same.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

The present invention relates to short peptides or salts thereof which can be modified with appropriate hydrophobic tails to generate amphiphilic molecules useful for the intracellular delivery of molecules of biological interest. Thus, the invention also relates to the amphiphilic molecules and to the complexes between said amphiphilic molecules and the molecules of biological interest. In addition, the invention refers to the use of said peptides, said amphiphilic molecules and said complexes for the delivery of molecules of biological interest. The invention relates to said peptides or salts thereof, said amphiphilic molecules and said complexes for use in medicine, particularly for use as a vaccine. Methods for the preparation of the amphiphilic molecules and the complexes of the invention are also contemplated. Finally, the invention relates to novel amino acids useful in the synthesis of the peptides and molecules of the invention.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
• C07K 19/00 - Hybrid peptides
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C07C 211/00 - Compounds containing amino groups bound to a carbon skeleton
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

A system for implantation by sterilisation techniques. A sterile implantation system comprising a heat-sensitive polymeric matrix that modifies its structure in the presence of a compressed gas or supercritical fluid to produce a solid or semi-solid with porosity greater than 60%.

IPC Classes  ?

• A61L 2/18 - Liquid substances
• A61L 2/07 - Steam

Abstract

Polymers for gene therapy. The present invention relates to a polymer, more specifically a polyphosphazene polymer, that is useful for gene therapy. The invention also relates to a complex comprising the polymer, the method for producing same and uses thereof.

IPC Classes  ?

• C08G 79/025 - Polyphosphazenes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a supramolecular fluid for use in redox reactions. More specifically, the fluid of the invention comprises a quaternary ammonium salt. The invention also relates to compositions of the quaternary ammonium salt and to the uses of same.

IPC Classes  ?

• H01M 8/18 - Regenerative fuel cells, e.g. redox flow batteries or secondary fuel cells

Abstract

The present invention relates to a compound for splitting water by means of an electrolysis process. More specifically, the compound is useful for producing hydrogen and for producing oxygen. The invention also relates to an electrode, a battery and the methods for preparing the electrode.

IPC Classes  ?

• C07F 9/00 - Compounds containing elements of Groups 5 or 15 of the Periodic Table
• B01J 37/00 - Processes, in general, for preparing catalystsProcesses, in general, for activation of catalysts
• B01J 37/04 - Mixing
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 11/065 - Carbon
• C25B 11/085 - Organic compound

Abstract

Described is a device that allows the chemical composition of gases existing, or released, inside a reactor or other type of chamber or cell to be monitored over time in an automated manner and in real time. Also described is the use of the device to monitor a reaction that causes the release of gases (e.g. combustion, photolysis or electrolysis of water, which comprises the production of hydrogen and oxygen), to monitor the decomposition of organic matter or to monitor the release of a dissolved gas, among others.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01D 21/02 - Measuring two or more variables by means not covered by a single other subclass

Abstract

A method of using a boron cluster as a transmembrane carrier to transport a bioactive molecule across a membrane of a cell or a vesicle. The method includes providing a boron cluster having at least one hydrogen atom and/or at least one halogen atom, providing a bioactive molecule which is cationic, zwitterionic or not charged, so that the bioactive molecule is not negatively charged, and using the boron cluster as a transmembrane carrier to transport the bioactive molecule across the membrane of the cell or the vesicle.

IPC Classes  ?

• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient

Abstract

The present invention relates to a process for processing glass using a laser source. More particularly, this process comprises making structures with different geometries and depths in glass substrates, using a subaquatic indirect laser ablation method.

IPC Classes  ?

• B23K 26/18 - Working by laser beam, e.g. welding, cutting or boring using absorbing layers on the workpiece, e.g. for marking or protecting purposes
• B23K 26/12 - Working by laser beam, e.g. welding, cutting or boring in a special environment or atmosphere, e.g. in an enclosure
• B23K 26/14 - Working by laser beam, e.g. welding, cutting or boring using a fluid stream, e.g. a jet of gas, in conjunction with the laser beamNozzles therefor

Abstract

The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• C07D 473/06 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
• C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to furano-diterpenes for use in the prevention and/or treatment of diseases involving cyclophilins. The present invention belongs to the field of biomedicine and pharmacological chemistry. More specifically, it relates to compounds of formula (1-5), isolated from Spongia tubulifera, for use in medicine, particularly in the prevention and/or treatment of diseases involving cyclophilins.

IPC Classes  ?

• C07D 307/92 - NaphthofuransHydrogenated naphthofurans
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

3 3 (1,25D) of the vitamin D receptor (VDR), the key biological results of these novel derivatives indicate that: a) these analogues show a similar cell differentiation, b) the proliferation of tumoral cell lines are significantly lower, c) great ability to activate target genes of 1,25D and d) high affinity to the VDR. Furthermore, one of the analogues induces a significant increase in the weight of some animals, which may suggest an increase in bone density.

IPC Classes  ?

• A61P 3/00 - Drugs for disorders of the metabolism
• C07F 7/08 - Compounds having one or more C—Si linkages

Abstract

A device for hyperdimensional computing comprising: an array of m x n 1-bit processing units; each processing unit comprising a 1-bit logic unit and a memory unit; at least one input terminal for receiving an input hypervector; n 1-bit multiplexers for selecting: the input of a processing unit in the first row, the input of a processing unit of the last row or the input of the at least one input terminal; wherein the array is arranged such that each processing unit is connected to its four nearest neighboring processing units, where: one neighboring processing unit for each processing unit of the first row of the array is the processing unit of the last row sharing the same column of the array; one neighboring processing unit for each processing unit of the last column of the array is the processing unit of the first column and next row; one neighboring processing unit for the processing unit at position m x n is the processing unit at position 1 x 1. Also, methods for manufacturing and using the device.

IPC Classes  ?

• G06F 7/544 - Methods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using non-contact-making devices, e.g. tube, solid state deviceMethods or arrangements for performing computations using exclusively denominational number representation, e.g. using binary, ternary, decimal representation using unspecified devices for evaluating functions by calculation
• G06N 3/063 - Physical realisation, i.e. hardware implementation of neural networks, neurons or parts of neurons using electronic means

Abstract

The invention relates to biodegradable microspheres for extended release of fenofibrate, injectable formulations comprising said microspheres and their use for the treatment of joint related disorders, such as osteoarthritis. The invention furthermore relates to a method of preparing said microspheres.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate

Abstract

Disclosed is a single-unit biotechnology method for simultaneously recovering polyhydroxyalkanoates (PHAs) and triacylglycerides (TAGs). The present invention relates to a method for producing biomass in the form of a mixed microbial culture containing PHAs and TAGs. More specifically, the method comprises certain steps that occur in a single discontinuous sequential reactor.

IPC Classes  ?

• C12P 7/625 - Polyesters of hydroxy carboxylic acids
• C12P 7/6445 - Glycerides
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C08G 63/78 - Preparation processes

Abstract

Disclosed is a single-unit biotechnology method for simultaneously recovering polyhydroxyalkanoates (PHAs) and triacylglycerides (TAGs). The present invention relates to a method for producing biomass in the form of a mixed microbial culture containing PHAs and TAGs. More specifically, the method comprises certain steps that occur in a single discontinuous sequential reactor.

IPC Classes  ?

• C12P 7/625 - Polyesters of hydroxy carboxylic acids
• C12P 7/6445 - Glycerides
• C12P 7/6463 - Glycerides obtained from glyceride producing microorganisms, e.g. single cell oil
• C08G 63/06 - Polyesters derived from hydroxy carboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxy carboxylic acids
• C08G 63/78 - Preparation processes
• C02F 3/12 - Activated sludge processes

Abstract

The present invention relates to metal-organic structures. More specifically, it relates to metal-ligand structures having a mesocate architecture. The present invention also relates to the method for producing said structures and the use thereof.

IPC Classes  ?

• C07C 335/04 - Derivatives of thiourea
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials

Abstract

The invention relates to compounds and compositions capable of silencing, in a specific manner, the mRNA of isoform beta of the PIAS2 protein, as well as to the use thereof for the treatment of cancer, and particularly anaplastic carcinoma of the thyroid.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the use of the polymerase chain reaction for detecting scuticociliates in samples, preferably scuticociliates which cause diseases in flat fish.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The invention discloses an immunogenic composition for the prevention of marine tenacibaculosis, a disease that affects marine and anadromous fish with great commercial value, comprising the strains Tenacibaculum maritimum CECT 30394 and Tenacibaculum soleae CECT 30393. The invention further includes its production method and the use thereof against said disease.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 39/02 - Bacterial antigens
• A61P 31/04 - Antibacterial agents

Abstract

Tenacibaculum maritimumTenacibaculum soleaeTenacibaculum soleae CECT 30393. The invention further includes its production method and the use thereof against said disease.

IPC Classes  ?

• C12N 1/20 - BacteriaCulture media therefor
• A61K 39/02 - Bacterial antigens
• A61P 31/04 - Antibacterial agents

Abstract

The invention relates to a lipopeptide biosurfactant for use in the treatment of scuticociliatosis in a marine organism susceptible to scuticociliatosis.

IPC Classes  ?

• A01N 63/50 - Isolated enzymesIsolated proteins
• A61K 35/74 - Bacteria
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A01N 63/27 - Pseudomonas
• A61P 33/02 - Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
• A01P 15/00 - Biocides for specific purposes not provided for in groups

Abstract

The present invention relates to a population of small extracellular vesicles (sEVs) for use in the treatment of obesity in a subject in need thereof, wherein the sEVs comprise at least one polynucleotide encoding a D168A dominant negative AMP-activated protein kinase alpha 1 (AMPKal-DN) mutant protein operably linked and under the control of a steroidogenic factor 1 (SF1) promoter, wherein the sEVs are engineered to transiently express in their outer membrane at least one fusion protein comprising the neurotrophic rabies virus (RVG) peptide fused to lysosome-associated membrane protein 2b. Said population is highly safe and effective, as the sEVs, when administered systematically, are capable of exerting their effect in the SF1 expressing neurons located in the ventromedial nucleus of the hypothalamus.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61P 3/04 - AnorexiantsAntiobesity agents
• C12N 15/52 - Genes encoding for enzymes or proenzymes

Abstract

The present invention relates to a population of small extracellular vesicles (sEVs) for use in the treatment of obesity in a subject in need thereof, wherein the sEVs comprise at least one polynucleotide encoding a D168A dominant negative AMP-activated protein kinase alpha 1 (AMPKal-DN) mutant protein operably linked and under the control of a steroidogenic factor 1 (SF1) promoter, wherein the sEVs are engineered to transiently express in their outer membrane at least one fusion protein comprising the neurotrophic rabies virus (RVG) peptide fused to lysosome-associated membrane protein 2b. Said population is highly safe and effective, as the sEVs, when administered systematically, are capable of exerting their effect in the SF1 expressing neurons located in the ventromedial nucleus of the hypothalamus.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 5/0784 - Dendritic cellsProgenitors thereof

Abstract

The present invention refers to an in vitro method for screening and/or selecting genes whose methylation status indicates whether a patient suffering from obesity is responding or will respond to a treatment with VLCKD. Moreover, the present invention refers to an in vitro method for monitoring or predicting whether a patient suffering from obesity is responding or will respond to VLCKD.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention refers to an in vitro method for screening and/or selecting genes whose methylation status indicates whether a patient suffering from obesity is responding or will respond to a treatment with VLCKD. Moreover, the present invention refers to an in vitro method for monitoring or predicting whether a patient suffering from obesity is responding or will respond to VLCKD.

IPC Classes  ?

• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The construction cell (1) comprises a first wooden chord (2) and a second wooden chord (3). The first chord (2) comprises a first side (4) located at a first end and having a height htc11, a second side (5) located at the opposite end and having a height htc12, a third side having a breadth br11, and a fourth side located opposite the third side and having a breadth br12. The second chord has a first side (8) located at a first extremity and having a height htt21, and a second side (9) at the opposite extremity thereof and having a height htt22, a third side with a breadth br21 and a fourth side, opposite the third side (10), with a breadth br22. The cell (1) further comprises at least one first web (11) with a height h1 and a breadth bw1, which is in contact with the first side (4) of the first chord (2) and with the first side (8) of the second chord (3), such that the first chord (2) and the second chord (3) are mechanically linked by means of at least said first web (11) and define an internal cavity (12) defined by the space located between the chords (2, 3) and the first web (11). The first web (11) is a wood fibre board with an average density greater than 1000 kg/m3 and less than 1300 kg/m3, and a thickness of 8 mm.

IPC Classes  ?

• E04C 3/12 - JoistsGirders, trusses, or truss-like structures, e.g. prefabricatedLintelsTransoms of wood, e.g. with reinforcements, with tensioning members
• E04B 7/22 - Roofs consisting of self-supporting slabs, e.g. able to be loaded the slabs having insulating properties, e.g. being laminated with layers of insulating material

Abstract

The present invention refers to an in vitro method for the diagnosis and/or prognosis of breast cancer. The method of the invention is carried out by determining the concentration level of proteins in erythrocytes or red blood cells (RBCs) which are present in- or isolated from patient blood samples.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to a composition which comprises an anionic surfactant, specifically an alkylbenzene sulphonate and an ionic liquid. The present invention further relates to the use of said composition in an enhanced crude oil recovery method.

IPC Classes  ?

• E21B 43/22 - Use of chemicals or bacterial activity
• C09K 8/584 - Compositions for enhanced recovery methods for obtaining hydrocarbons, i.e. for improving the mobility of the oil, e.g. displacing fluids characterised by the use of specific surfactants

Abstract

In vitro method for the diagnosis of viral infections. The present invention refers to an in vitro method for the diagnosis of viral infections, for selecting a therapy for a patient suffering a viral infection and/or for monitoring the response of vaccinated patients to a viral vaccine.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Abstract

The present invention is related to a non-invasive method for determining a vessel damage indicator in a patient. The invention is a computer implemented invention that characterize the blood flow inside the coronary tree by simulating numerical blood flow models based on CT-scan 3D images analysis. The simulated numerical blood flow model of the invention determines a vessel damage indicator as the rate between the pressure values at different locations of the artery.

IPC Classes  ?

• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• A61B 6/03 - Computed tomography [CT]
• A61B 6/00 - Apparatus or devices for radiation diagnosisApparatus or devices for radiation diagnosis combined with radiation therapy equipment
• G06T 7/00 - Image analysis
• G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

Disclosed is a pharmaceutical composition for use in treating inflammatory diseases. The present invention relates to a pharmaceutical composition comprising eprinomectin. The composition is useful for the anti-inflammatory treatment of inflammatory diseases, such as rheumatoid arthritis.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Abstract

Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 9/51 - Nanocapsules
• A61P 35/00 - Antineoplastic agents

Abstract

Polymers for gene therapy. The present invention relates to a polymer, more specifically a polyphosphazene polymer, that is useful for gene therapy. The invention also relates to a complex comprising the polymer, the method for producing same and uses thereof.

IPC Classes  ?

• C08G 79/025 - Polyphosphazenes
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Abstract

A system for implantation by sterilisation techniques. A sterile implantation system comprising a heat-sensitive polymeric matrix that modifies its structure in the presence of a compressed gas or supercritical fluid to produce a solid or semi-solid with porosity greater than 60%.

IPC Classes  ?

• A61L 2/16 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor using chemical substances
• A61L 2/18 - Liquid substances

Abstract

Compound for batteries. The present invention relates to a compound for splitting water by means of an electrolysis process. More specifically, the compound is useful for producing hydrogen and for producing oxygen. The invention also relates to an electrode, a battery, and the methods for preparing the electrode.

IPC Classes  ?

• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
• C01G 31/02 - Oxides
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water

Abstract

The present invention relates to a supramolecular fluid for use in redox reactions. More specifically, the fluid of the invention comprises a quaternary ammonium salt. The invention also relates to compositions of the quaternary ammonium salt and to the uses of same.

IPC Classes  ?

• H01M 6/04 - Cells with aqueous electrolyte
• C07C 211/62 - Quaternary ammonium compounds

Abstract

The present invention generally relates to particles, including nanocapsules or other nanoentities, comprising a polymer such as polysialic acid. The particles are able to access the interior of the cells, and/or to procure the intracellular release of the associated drugs. In 5 one aspect, the present invention is directed to nanocapsules or other entities having an exterior or surface comprising a polymer such as polysialic acid. In some cases, targeting moieties such as Lyp-1 or tLyp-1 peptide are bonded to the polymer, e.g., using aminoalkyl (C1-C4) succinimide or other linkers. These may be created, for example, by reacting a carboxylate moiety on a polymer with an aminoalkyl maleimide (C1-C4) or an aminoalkyl 10 (C1-C4) methacrylamide, and reacting the resulting aminoalkyl (C1-C4) maleimide or the aminoalkyl (C1-C4) methacrylamide to a cysteine or other sulfur group. Targeting moieties are bonded to the polymer, for example, by reacting a carboxylate moiety on a polymer with a N-hydroxysuccinimide or a carbodiimide, and reacting the intermediate formed with a lysine or arginine group on a targeting peptide to produce polymer-amide-peptide. Other 15 aspects of the invention are generally directed to methods of making or using such compositions, kits including such compositions, or the like.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

IPC Classes  ?

• C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 239/42 - One nitrogen atom
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 495/04 - Ortho-condensed systems
• C07F 5/02 - Boron compounds

Abstract

There is provided an invention relating to compositions and therapeutic uses of atomic quantum clusters (AQCs), in particular compositions consisting essentially of AQCs comprising 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

IPC Classes  ?

• A61K 33/38 - SilverCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to functionalized isonitrile compounds, formed by means of multicomponent environmentally friendly reactions, suitable for coupling to functional molecules such as biomolecules, APIs, chromophore and fluorophore molecules. The invention also relates to conjugates between said isonitrile compounds and functional molecules, which are useful in the synthesis of pharmaceutic drugs or tools, fluorescent molecules and labels, polymeric smart materials. The invention furthermore provides a kit for the in-vitro preparation of the functionalized isontrile compounds and conjugates. The invention also contemplates the medical use of said compounds and conjugates.

IPC Classes  ?

• C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• C07D 231/14 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 239/42 - One nitrogen atom
• C07D 241/04 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 495/04 - Ortho-condensed systems
• C07F 5/02 - Boron compounds
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 35/00 - Antineoplastic agents
• A61K 31/22 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin

Abstract

Pharmaceutical composition for use in the prophylactic and/or therapeutic treatment of dyskinesias induced by L-DOPA. The present invention relates to the pharmaceutical field, more particularly to the use of Rho kinase inhibitors for treating or preventing dyskinesias induced by L-DOPA.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/14 - Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Abstract

The present invention is related to systems of administration of enzymes or other proteins, preferably for use in enzyme replacement therapy (ERT), in particular for the treatment of Lysosomal diseases. In particular, the invention encompasses the preparation of a composition based on nanostructured lipid systems and its use in the manufacture of a therapeutic product.

IPC Classes  ?

• A61K 9/50 - Microcapsules
• A61K 38/46 - Hydrolases (3)
• A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue

Abstract

The invention relates to a modular sterilizable system for organoid culture, which comprises a culture module with one or more sample wells and an stirring module that includes an air compressor with flow control means, a nozzle for each sample well, a pressure sensor and a controller that acts on the flow control means according to the pressure reading. The method for sterilizing the system consists in decoupling the two modules, removing the culture module and sterilizing it. The system can have a module for monitoring the growth of the organoids, as well as a module for controlling the physiochemical parameters of the culture.

IPC Classes  ?

• C12M 1/04 - Apparatus for enzymology or microbiology with gas introduction means
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

The present invention relates to a new type of heterogeneous catalysts formed by a three-dimensional ceramic metal (cermet) structure, obtained by direct writing techniques (3D printing). One or more metals and one or more ceramic compounds in adequate proportions are used to make a paste (ink), whose rheological properties allow it to be extruded by 3D printing to form a pre-designed three-dimensional structure. After forming, the structure is processed thermally to obtain the consolidated cermet, with catalytically active metal phases in its body and on its surface.

IPC Classes  ?

• B01J 35/02 - Solids
• C09D 11/30 - Inkjet printing inks
• B41M 1/00 - Inking and printing with a printer's forme

Abstract

Transgenic non-human models for lipodystrophy and/or PELD. The present invention refers transgenic non-human models for lipodystrophy and/or PELD. More specifically, the present invention also refers to a method for screening candidate compounds for use as drugs for treating lipodystrophy and/or PELD.

IPC Classes  ?

• A01K 67/027 - New or modified breeds of vertebrates
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated The invention also relates to the pharmaceutical compositions having such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

IPC Classes  ?

• A61K 33/243 - PlatinumCompounds thereof
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/52 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61P 35/00 - Antineoplastic agents

Abstract

The invention relates to compounds and compositions capable of specifically silencing mRNA expression of isoform PIAS2-beta, in addition to using them for treating cancer and, in particular, anaplastic thyroid carcinoma.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of pharmaceuticals, more specifically to the use of rho kinase inhibitors for the treatment or prevention of L-DOPA-induced dyskinesia.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Peptides for use as senotherapeutic agents. The present invention refers to senotherapeutic agents comprising different peptides for use in the prevention or treatment of aging- associated diseases caused by the persistence and accumulation of senescent cells.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/00 - Drugs for skeletal disorders
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 3/00 - Drugs for disorders of the metabolism
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 27/00 - Drugs for disorders of the senses
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to the field of pharmaceuticals, more specifically to the use of rho kinase inhibitors for the treatment or prevention of L-DOPA-induced dyskinesia.

IPC Classes  ?

• A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

IPC Classes  ?

• C07D 307/89 - Benzo [c] furansHydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
• C07D 307/88 - Benzo [c] furansHydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Abstract

Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.

IPC Classes  ?

• A61K 31/60 - Salicylic acidDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

Intracellular delivery of anti-KRAS antibodies formulated into nanocapsules Provided herein is a composition, comprising: a plurality of nanoentities comprising an inner core surrounded by an outer shell, the outer shell comprising a polymer, the inner core comprising at least one hydrophobic compound, wherein the nanoentities comprise a pharmaceutical agent, wherein the pharmaceutical agent is an antibody or a fragment thereof, wherein the antibody or the fragment thereof binds to an epitope of an activated mutated KRAS protein. These anti-KRAS antibodies formulated into particular nanoentities are able to be intracellular delivered and further, are able to perform their biological activity inside the cell, thus being useful in the treatment of cancer and other disease associated with a mutation in a KRAS gene.

IPC Classes  ?

• A61K 31/60 - Salicylic acidDerivatives thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The RET/GDNF survival pathway plays an important role in acromegaly. Hence, ARF gene expression levels are predictive of a good response or resistance to first line therapy with a first-generation analogue of somatostatin. Additionally, Tyrosine Kinase Inhibitor (TKI) able to block the RET/GDNF survival pathway, in particular Sorafenib could be useful for the treatment of acromegaly resistant to first line therapy, by counteracting the survival effect of GDNF or NRTN factors, or the combination of both.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

In vitroin vitroin vitro method for the diagnosis of viral infections, for selecting a therapy for a patient suffering a viral infection and/or for monitoring the response of vaccinated patients to a viral vaccine.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

The present invention refers to process for oxidation of organosulfur compounds comprising metal AQCs having between 5 and 13 metal atoms as catalyst. Additionally, the present invention refers to the use of the metal AQCs having between 5 and 13 metal atoms as catalyst in the oxidation of organosulfur compounds and to a chemical composition comprising organosulfur compounds and metal AQCs having between 5 and 13 metal atoms.

IPC Classes  ?

• C10G 27/04 - Refining of hydrocarbon oils, in the absence of hydrogen, by oxidation with oxygen or compounds generating oxygen
• B01J 35/02 - Solids
• B01J 23/52 - Gold
• B01J 23/72 - Copper
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

The present invention relates to compounds that can be defined as compounds derived from lithocholic acid and the metabolites thereof. For this reason, the compounds of the invention are named using the steroid numbering system. More particularly, the invention relates to compounds derived from lithocholic acid, to methods for obtaining same, to intermediate compounds from the synthesis thereof, and to their applications.

IPC Classes  ?

• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention refers to a polymeric composite, a process for preparing said polymeric composite, a polymeric composite obtainable by said process and the use of stabilizers in vinyl polymers.

IPC Classes  ?

• C08K 3/08 - Metals
• C08J 7/06 - Coating with compositions not containing macromolecular substances

Abstract

There is provided an invention relating to compositions and therapeutic uses of atomic quantum clusters (AQCs), in particular compositions consisting essentially of AQCs comprising 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

IPC Classes  ?

• A61K 33/38 - SilverCompounds thereof
• A61P 35/00 - Antineoplastic agents

Abstract

A method and system for removing phosphorus, organic carbon and nitrogen using aerobic granular biomass and pulsed aeration. The present invention relates to a method and system for enhancing the growth of biopolymer-accumulating organisms in order to remove phosphorus, organic carbon and nitrogen from industrial or urban wastewater using aerobic granular biomass and pulsed aeration. The system and method use a sequential batch reactor (SBR) with anaerobic feed/reaction or with unreacted feed. The pulsed aeration has a frequency of a few seconds.

IPC Classes  ?

• C02F 3/02 - Aerobic processes
• C02F 3/12 - Activated sludge processes
• C02F 3/34 - Biological treatment of water, waste water, or sewage characterised by the microorganisms used

Abstract

There is provided an invention relating to compositions and therapeutic uses of atomic quantum clusters (AQCs), in particular compositions consisting essentially of AQCs comprising 5 zero-valent transition metal atoms for use in the treatment of a cell proliferative disorder.

IPC Classes  ?

• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• A61P 35/00 - Antineoplastic agents
• A61K 33/38 - SilverCompounds thereof

Abstract

Obestatin for use in the treatment of peripheral nerve damages or injuries.The present invention refers to the use obestatin in the treatment of peripheral nerve damages or injuries.

IPC Classes  ?

• A61K 38/25 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• C07K 14/60 - Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies

Abstract

The invention relates to a modular sterilisable system for organoid culture, which comprises a culture module with one or more sample wells and an agitation module that includes an air compressor with flow control means, a nozzle for each sample well, a pressure sensor and a controller that acts on the flow control means according to the pressure reading. The method for sterilising the system consists in decoupling the two modules, removing the culture module and sterilising it. The system can have a module for monitoring the growth of the organoids, as well as a module for controlling the physiochemical parameters of the culture.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• B01F 13/02 - Mixers with gas agitation, e.g. with air supply tubes

Abstract

The present invention relates generally to methods for characterization of fluids, and, particularly, to methods of determining an interfacial tension between a first liquid and a second fluid, the method comprising the steps of: (a) introducing the second fluid into the first liquid at a constant flow-rate so as to cause the second fluid to periodically form successive droplets or bubbles; (b) recording a heat change of step (a) as a function of time, obtaining a periodic heat versus time profile; (c) obtaining the period of the heat change recorded in step (b); (d) providing a calibrated relationship of the interfacial tension as a function of period for said constant flow-rate and said second fluid; and (e) correlating the period obtained in step (c) with the calibrated relationship, and determining the interfacial tension between the first liquid and the second fluid for said constant flow-rate.

IPC Classes  ?

• G01N 13/02 - Investigating surface tension of liquids
• G01N 25/20 - Investigating or analysing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity

Abstract

The present invention relates to the use of ruthenium(II) complexes for preparing a medicinal product for treating cancer, particularly cancer comprising cancer stem cells. Said ruthenium complexes are capable of selectively metallating guanine quadruplexes, thus resulting in increased expression of the c-MYC oncogene. This increase in the proportion of c-MYC may promote the differentiation of cancer stem cells.

IPC Classes  ?

• A61P 35/00 - Antineoplastic agents
• A61K 31/555 - Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol

Abstract

A computer-implemented method and system for detecting small objects on an image using convolutional neural networks. The method comprises: applying convolution operations (210) to an input image (102) to obtain a first set of convolutional layers (212) and an input feature map (302); analyzing the input feature map (302) to determine a first set of candidate regions (222) containing candidate objects; arranging the first set of candidate regions (222) to form a reduced feature map (228); applying convolution operations (230) to the reduced feature map (228) to obtain a second set of convolutional layers (232) and an output feature map (502); applying a Region Proposal Network (240) to the output feature map (502) to obtain a second set of candidate regions (242) containing candidate objects; classifying and applying bounding box regression (250) to each candidate region of the second set (242) to obtain, for each candidate region, a class score as a candidate object and a bounding box in the input image (102).

IPC Classes  ?

• G06K 9/62 - Methods or arrangements for recognition using electronic means
• G06K 9/00 - Methods or arrangements for reading or recognising printed or written characters or for recognising patterns, e.g. fingerprints
• G06K 9/32 - Aligning or centering of the image pick-up or image-field
• G06K 9/46 - Extraction of features or characteristics of the image

Abstract

The invention relates to nanosystems with complexes. The present invention relates to a nanosystem characterised by having a complex and a cover, to the methods for obtaining same, to complexes and the uses thereof.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• B82Y 5/00 - Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
• B82Y 40/00 - Manufacture or treatment of nanostructures

Abstract

The present invention is related to systems of administration of enzymes or other proteins, preferably for use in enzyme replacement therapy (ERT), in particular for the treatment of Lysosomal diseases. In particular, the invention encompasses the preparation of a composition based on nanostructured lipid systems and its use in the manufacture of a therapeutic product.

IPC Classes  ?

• A61K 9/50 - Microcapsules

Abstract

The present invention relates to magnetic nanoparticles based on iron oxide having cubic shape, suitably functionalized for the release of targeting chemotherapeutic agents, i.e. selectively in the tumors being treated; the invention also relates to the pharmaceutical compositions comprising such nanoparticles and to their use in combined oncological therapies of hyperthermia and chemotherapy, useful in particular in the treatment of ovarian tumors.

IPC Classes  ?

• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a cell penetrating peptide with or without a ligand comprising a scaffold of at least two hydrophobic blocks and at least two cationic blocks, each cationic blocks alternating with one hydrophobic block; wherein the total number of amino acids is comprised between 5 and 40, and wherein each of said hydrophobic blocks individually considered consist of one or more hydrophobic amino acids, wherein at least one of said hydrophobic amino acids is selected from the group consisting of leucine, alanine and iso leucine; wherein said at least two hydrophobic blocks comprise at least a leucine amino acid; and each of said cationic blocks individually considered comprise at least one cationic amino acid having a side chain comprising a nitrogen atom, preferably one which is protonated under physiological conditions.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

The invention relates to a fusion protein comprising glucose-6-phosphatase 2 protein and a polypeptide derived from the Avian or Mammalian orthoreovirus muNS protein, to a method for producing said protein, and to the use of said protein to treat type 1 diabetes.

IPC Classes  ?

• C07K 14/14 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/46 - Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
• A61K 35/765 - ReovirusRotavirus
• A61K 38/46 - Hydrolases (3)
• A61P 3/08 - Drugs for disorders of the metabolism for glucose homeostasis

Abstract

The present invention relates to anti-leptin affinity ligands (e.g. anti-leptin antibodies) that specifically bind leptin and reduce its serum levels for use in a method of treating a leptin- resistance associated disease, such as obesity and/or overweight, in a subject in need thereof. It further relates to compositions comprising the same, as well as methods of treatment comprising administration of a therapeutically effective dosage thereof.

IPC Classes  ?

• A61P 3/04 - AnorexiantsAntiobesity agents
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The invention relates to a continuous method for treating wastewater with organic material with granular biomass, which comprises: (a) a first aerobic complete-mix reactor, the treated water flowing to a second reactor; (b) a second aerobic complete-mix reactor with granular biomass; (c) a decanter with a liquid surface speed greater than or equal to 1 m/h; and (d) recovering the treated water of the supernatant from the decanter. The volume of the first aerobic tank is between 1/10 and 1/3 (or 10-33%) of the total reaction volume, aeration in both tanks being applied at a surface speed of between 0.5 and 5 cm/s, and the granular biomass decanted in step (c) is recirculated to the first reactor while the biomass is allowed to pass from the first reactor to the second reactor at a recirculation ratio between 0.25 and 1. These conditions allow the formation and maintenance of granules of aerobic biomass in continuous flow.

IPC Classes  ?

• C02F 3/02 - Aerobic processes
• C02F 3/12 - Activated sludge processes
• C02F 9/12 - Irradiation or treatment with electric or magnetic fields
• C02F 9/14 - Multistep treatment of water, waste water or sewage at least one step being a biological treatment

Abstract

Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

IPC Classes  ?

• A61K 38/45 - Transferases (2)

Abstract

Gracilin A congeners and methods for their use as immunosuppressive and neuroprotective agents.

IPC Classes  ?

• C07D 307/89 - Benzo [c] furansHydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07D 307/88 - Benzo [c] furansHydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3

Abstract

The present invention refers to a method for detoxification of contaminated substances. In addition, the present invention is directed to a composition comprising a contaminated substance and a particulate magnetic composite material and to the use of a particulate magnetic composite material for detoxification of a contaminated substance.

IPC Classes  ?

• B03C 1/01 - Pretreatment specially adapted for magnetic separation by addition of magnetic adjuvants
• B03C 1/033 - Component partsAuxiliary operations characterised by the magnetic circuit
• A23C 7/04 - Removing unwanted substances from milk
• B01D 11/02 - Solvent extraction of solids
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• H01F 1/00 - Magnets or magnetic bodies characterised by the magnetic materials thereforSelection of materials for their magnetic properties
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• A23L 5/20 - Removal of unwanted matter, e.g. deodorisation or detoxification
• C02F 1/48 - Treatment of water, waste water, or sewage with magnetic or electric fields